About RegenEra Ventures
RegenEra Ventures is a global VC fund focusing on early-stage biotech companies in the field of regenerative medicine and diseases of ageing. Founded in 2025, we combine a strong industry network with an experienced investment team and scientific expertise.
Our Mission
RegenEra bridges the gap between innovative research and clinical validation in regenerative and geromedicine.
Our Focus
We operate globally with primary focus on Europe as a lead/co-lead investor for Seed to Series A companies with a science-driven approach.
Our Team
General Partners
Patrick Burgermeister
General Partner
Masters in Molecular Biology and Economics, CFA
patrick@regeneravc.com
Aksana Labokha
General Partner
PhD in Biochemistry
Partner
General Partner
PhD in Molecular Biology, CFA
Partner
General Partner
Master in Management
Scientific Advisors
Brian Kennedy
Longevity Biology
Globally renowned longevity researcher, deep expertise in ageing biomarkers and therapeutic interventions.
Guido Kroemer
Ageing Biology
World renowned professor in ageing biology
Alejandro Ocampo
Reprogramming
Pioneer in cellular reprogramming with groundbreaking research in aging and regenerative medicine.
James B. Summers
Neuroscience
Industry veteran with 30+ years in neuroscience and extensive experience in drug development.
Oxana Polyakova
Cell therapy
Industry expert in cellular therapies with deep expertise in immunological interventions.
Richard Sainson
Immunology
Industry expert in immunology with extensive experience in therapeutic development.
Melanie Lee
Strategy
30+ years in C-level roles at pharma and VC funds
Nigel Clark
Business Development
BD veteran with 30+ years in pharma
Laura Millichamp
Regulatory
Regulatory and CMC expert
Investment Focus
RegenEra bridges the gap between innovative research and clinical validation in regenerative and geromedicine.
Cardiometabolic
Targeting cardiovascular and metabolic diseases through innovative therapeutic approaches and biomarker development.
Neurodegenerative
Advancing treatments for Alzheimer's, Parkinson's, and other neurodegenerative conditions through cutting-edge research.
Immunology/Inflammation
Developing immunomodulatory therapies and anti-inflammatory treatments for age-related immune dysfunction.
Market Opportunity
Diseases of ageing are driven by demographic shifts and our advancing scientific understanding of the aging processes. This convergence creates unprecedented investment opportunities as global populations age and demand for age-related disease solutions accelerates.
Invest in the Future of Healthspan
Healthspan innovation is reshaping the future of healthcare—impacting every facet of life and unlocking unprecedented investment potential. As global populations age, the demand for solutions to chronic, degenerative diseases is accelerating. At the same time, breakthroughs in the biology of ageing are driving a fundamental shift: from treating individual symptoms to targeting the root cause of decline.
Addressing the biology of ageing offers a more scalable and durable return profile than single- disease approaches. The healthspan market is projected to reach $367 billion by 2032, growing at over 30% annually, as scientific and commercial momentum builds.
*Annual Longevity Investment Report 2023, Longevity Technology
RegenEra Ventures is at the forefront of this revolution—backing visionary founders advancing the future of regenerative medicine and tackling diseases of ageing. We partner with forward-thinking investors who share our commitment to transforming how the world ages— scientifically, socially, and economically.
For further information on investment opportunities, please reach out to us:
investors@regeneravc.comNews & Events
Upcoming Events
Stay tuned for announcements about upcoming conferences, webinars, and industry events where RegenEra Ventures will be participating.
Past Presentations
Access our previous presentations, interviews, and thought leadership content on regenerative medicine and healthspan investing.
For media inquiries or speaking opportunities, please contact us:
info@regeneravc.comContact Us
We're interested in speaking with founders and researchers in regenerative medicine targeting diseases of ageing.